Liraglutide for Diabetes
Trial Summary
What is the purpose of this trial?
The investigators recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. These effects are more pronounced in people with early type 2 diabetes (T2DM) in keeping with increased expression of PC-1/3 and GLP-1 that is observed in diabetic islets. However, its regulation is at present unknown. There is evidence that α-cell proglucagon processing is subject to paracrine regulation by the β-cell3. It is unclear if the effects of GLP1R agonism on islet GLP-1 differ in Type 1 diabetes (T1DM) compared to T2DM. This experiment will examine the effect of glycemic control ± a GLP1R agonist on islet GLP-1 in people with (T2DM) and without (T1DM) β-cells.
Research Team
Adrian Vella, MD
Principal Investigator
Mayo Clinic
Eligibility Criteria
This trial is for individuals with Type 1 or Type 2 Diabetes who are interested in how different treatments affect their insulin-producing cells. Specific eligibility criteria were not provided, so participants should inquire about detailed requirements.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either placebo or 0.6mg Liraglutide daily for 30 days
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Liraglutide
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor